On March 8, 2006, the Federal Trade Commission ("FTC") announced a Consent Agreement (subject to final approval) that will allow Allergan, Inc. ("Allergan") to acquire Inamed Corporation ("Inamed"). However, the FTC has mandated that Allergan divest the development and distribution rights of cosmetic botulinum toxin (tentatively branded "Reloxin") and return them to Ipsen, Ltd. ("Ipsen")....

This service is completely FREE but for the full article and thousands of other articles from 100+ countries please tell us about yourself by registering (and yes, our lawyers like to think you've read our Disclaimer). It only takes 30 seconds and as well as great content you get articles more relevant to you and other advanced features like an optional personalised once-weekly news alert and forward-to-colleague capabilities. We'll also remember your details so you don't have to login again - if you've registered before please login here or if you've forgotten your username click here and we'll remind you. We appreciate your time is important and will respect your privacy - THANK YOU for registering.

Specific Questions relating to this article should be addressed directly to the author.

Do you have a question for the author?